0
Seems like even if it lowers hunger, habits would overcome that at some point. Is this the reason for the limit?
The plateau is primarily biological, not behavioral — neurons in the brain stop sustaining the chemical signal that suppresses appetite, independent of whether habits have kicked in.
Why it matters: This distinction matters because it points to a fixable molecular failure, not a willpower problem, which is why a lung drug (roflumilast) can potentially reset the effect.
- The NIH research found that only neurons which hold a sustained spike of cyclic AMP keep suppressing appetite — others lose their signal quickly, likely because brain cells actively internalize (hide) their own GLP-1 receptors after repeated exposure.
- Blocking PDE4, the enzyme that breaks down cAMP, with roflumilast restored the suppression signal in mice — a purely biochemical fix, with no behavior change required.
- Behavioral adaptation (eating around reduced hunger, returning to food-reward habits) almost certainly contributes in practice, but the NIH study shows the drug itself loses neurological efficacy before habits could fully account for the stall.
- The ~14-month plateau timeline lines up with receptor desensitization patterns seen in other long-term drug use, not with the typical window for habit formation or erosion.
Room for disagreement
- Some obesity researchers argue the plateau is partly metabolic adaptation — the body burning fewer calories at lower weight — not just a drug signal problem, meaning no amount of neurological boosting fully overcomes energy-balance math.
- Behavioral scientists note that GLP-1's hunger suppression changes food preferences, not just hunger volume; patients who re-adopt high-calorie eating patterns may be hitting a behavioral ceiling that the cAMP story alone doesn't explain.
AI-generated with web search — may be wrong. Check the linked sources.
